Evogene (EVGN) AI Stock Analysis

• Market Cap: $10.63M
• Dividend Yield: N/A
• Average Volume (3M): 115.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -28.72%
• EPS Growth: 43.01%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 8,716,410
• 10 Day Avg. Volume: 235,429
• 30 Day Avg. Volume: 115,158
• PEG Ratio: 0.01
• Price to Book (P/B): -7.34
• Price to Sales (P/S): 1.25
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 1.52
• Enterprise Value/Revenue: 2.40
• Enterprise Value/Gross Profit: 5.13
• Enterprise Value/Ebitda: -1.37
• 1Y Price Target: $3.50
• Price Target Upside: 180.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

Evogene's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and high leverage. While the earnings call provided some positive developments, such as revenue growth and strategic initiatives, the ongoing financial challenges and bearish technical indicators weigh heavily on the stock's outlook.

Positive Factors

Strategic Partnership

The partnership with Google Cloud enhances Evogene's AI-driven platform, potentially accelerating innovation in drug discovery and agriculture, strengthening its market position.

Revenue Growth

The revenue increase, driven by strong seed sales, indicates successful product adoption and potential for continued growth in core markets.

Cost Reduction

Effective cost management through reduced R&D and marketing expenses enhances operational efficiency, improving financial stability.

Negative Factors

Declining Revenue Growth

Declining revenue growth reflects challenges in maintaining market share and competitiveness, potentially impacting long-term viability.

High Leverage

High leverage and negative equity indicate potential solvency risks, limiting financial flexibility and increasing vulnerability to market fluctuations.

Negative Cash Flow

Negative cash flow suggests inefficiencies in operations, requiring strategic changes to improve cash generation and ensure sustainability.

Evogene Business Overview & Revenue Model

Company Description

Evogene Ltd. (NASDAQ: EVGN) is a biotechnology company focused on the development of innovative products for the agriculture, food, and pharmaceutical industries. Utilizing its proprietary computational biology platform, the company aims to improve crop yield and resilience through the discovery of new genes and traits. Evogene's core products include seed traits for crops, bio-stimulants, and agricultural chemicals designed to enhance plant growth and protection against pests and diseases.

How the Company Makes Money

Evogene generates revenue primarily through the commercialization of its proprietary technologies and products in the agriculture and pharmaceutical sectors. Key revenue streams include licensing agreements with agricultural companies for its seed traits and technologies, partnerships with industry leaders for co-development projects, and the sale of bio-stimulants and other agricultural solutions. Additionally, the company benefits from strategic collaborations and joint ventures that provide funding and resources for its research and development efforts, further contributing to its earnings.

Evogene Financial Statement Overview

Summary

Evogene is facing significant financial challenges, with declining revenues, negative margins, and high leverage. The cash flow issues further exacerbate the situation, indicating a need for strategic restructuring or additional capital to stabilize operations.

Income Statement

Evogene's income statement reveals significant challenges. The company has experienced declining revenue growth, with a negative growth rate in the TTM period. Margins are under pressure, with a negative net profit margin and EBIT margin, indicating ongoing losses. The gross profit margin has decreased from previous years, reflecting reduced efficiency in cost management.

Balance Sheet

The balance sheet shows a concerning financial structure, with negative stockholders' equity in the TTM period, leading to a negative debt-to-equity ratio. This indicates high leverage and potential solvency risks. The return on equity is positive due to negative equity, but this is misleading as it reflects financial distress rather than profitability.

Cash Flow

Cash flow analysis highlights ongoing cash burn, with negative operating and free cash flows. The free cash flow growth rate is negative in the TTM period, and the operating cash flow to net income ratio is negative, indicating inefficiencies in converting income into cash. The free cash flow to net income ratio is slightly above 1, but this is due to both metrics being negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.74M	8.51M	5.64M	1.68M	930.00K	1.04M
Gross Profit	3.15M	5.83M	1.40M	766.00K	163.00K	466.00K
EBITDA	-11.78M	-15.48M	-23.20M	-26.93M	-27.80M	-23.18M
Net Income	-14.25M	-16.48M	-23.88M	-26.64M	-27.79M	-23.37M
Balance Sheet
Total Assets	33.93M	39.86M	51.10M	56.13M	76.30M	71.92M
Cash, Cash Equivalents and Short-Term Investments	11.69M	15.31M	31.06M	35.35M	53.87M	48.23M
Total Debt	12.69M	12.87M	11.51M	11.93M	2.67M	2.44M
Total Liabilities	21.55M	25.03M	22.42M	21.34M	12.88M	15.03M
Stockholders Equity	-3.55M	-1.45M	12.05M	27.93M	54.03M	46.05M
Cash Flow
Free Cash Flow	-18.20M	-20.33M	-22.36M	-24.85M	-25.56M	-20.20M
Operating Cash Flow	-17.62M	-19.70M	-21.58M	-23.68M	-24.84M	-19.51M
Investing Cash Flow	7.34M	9.62M	-4.54M	13.27M	-20.44M	9.41M
Financing Cash Flow	9.16M	4.66M	18.15M	9.34M	30.28M	20.37M

Evogene Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.23, and below the 200-day MA of 1.29, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 57.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EVGN.

Evogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBIO	45 Neutral	$26.13M	―	-101.52%	―	77.78%	84.08%
BOLT	45 Neutral	$9.67M	-0.19	-81.33%	―	-62.68%	23.94%
PHGE	44 Neutral	$9.99M	-0.37	-99.35%	―	―	80.30%
EVGN	43 Neutral	$10.63M	-0.54	―	―	-28.72%	43.01%
KZIA	31 Underperform	$12.80M	-0.26	―	―	-98.25%	63.05%
WINT	28 Underperform	$2.77M	―	-169.59%	―	―	85.35%

Evogene Corporate Events

Evogene Ltd. Releases Financial Results for First Half of 2025

Evogene Ltd. has released its unaudited condensed consolidated financial statements for the six-month period ending June 30, 2025. The report, submitted to the SEC, includes an analysis of the company’s financial condition and operational results for the specified period. This financial disclosure is crucial for stakeholders as it provides insights into the company’s current financial health and strategic positioning within the biotechnology sector.

Evogene Partners with Google Cloud to Enhance AI-Driven Molecular Discovery

On September 10, 2025, Evogene Ltd. announced a strategic collaboration with Google Cloud to enhance its AI-driven molecular discovery platform, ChemPass AI. This partnership aims to accelerate innovation in drug discovery and agriculture by leveraging Google’s infrastructure to optimize molecular design across multiple parameters, significantly improving accuracy and efficiency. This collaboration is expected to strengthen Evogene’s market position by expanding its capabilities in delivering innovative solutions to the pharmaceutical and agricultural sectors.

Evogene Announces Q2 2025 Financial Results and Strategic Shift to AI

On August 19, 2025, Evogene Ltd. announced its financial results for the second quarter of 2025, revealing a strategic shift towards AI-driven innovation. The company reported increased revenues of $3.2 million for the first half of 2025, driven by higher seed sales from Casterra, despite a decrease in AgPlenus revenues. Evogene completed the sale of Lavie Bio’s activities and the MicroBoost AI for Ag platform, boosting its cash position and aligning with its strategic focus on ChemPass AI. The company also implemented significant workforce reductions and restructuring plans to enhance operational efficiency and focus on its core technology, positioning itself for growth in the pharmaceuticals and agriculture sectors.

Evogene Shareholders Approve Proposals at Annual Meeting

On August 18, 2025, Evogene Ltd. announced that its shareholders approved all proposals at the annual general meeting, which was held after a one-week adjournment. This approval, in accordance with Israeli Companies Law, signifies a strategic alignment with the company’s goals and may impact its operational strategies and stakeholder interests.